Alkali activation is studied as a potential technology to produce a group of high performance building materials from industrial residues such as metallurgical slag. Namely, slags containing aluminate and silicate form a useful solid material when activated by an alkaline solution. The alkali-activated (AA) slag-based materials are promising alternative products for civil engineering sector and industrial purposes. In the present study the locally available electric arc furnace steel slag (Slag A) and the ladle furnace basic slag (Slag R) from different metallurgical industries in Slovenia were selected for alkali activation because of promising amorphous Al/Si rich content. Different mixtures of selected precursors were prepared in the Slag A/Slag R ratios 1/0, 3/1, 1/1, 1/3 and 0/1 and further activated with potassium silicate using an activator to slag ratio of 1:2 in order to select the optimal composition with respect to their mechanical properties. Bending strength of investigated samples ranged between 4 and 18 MPa, whereas compressive strength varied between 30 and 60 MPa. The optimal mixture (Slag A/Slag R = 1/1) was further used to study strength development under the influence of different curing temperatures at room temperature (R.T.), and in a heat-chamber at 50, 70 and 90 °C, and the effects of curing time for 1, 3, 7 and 28 days was furthermore studied. The influence of curing time at room temperature on the mechanical strength at an early age was found to be nearly linear. Further, it was shown that specimens cured at 70 °C for 3 days attained almost identical (bending/compressive) strength to those cured at room temperature for 28 days. Additionally, microstructure evaluation of input materials and samples cured under different conditions was performed by means of XRD, FTIR, SEM and mercury intrusion porosimetry (MIP).

Alkali-activated materials (AAMs) represent a promising alternative to conventional building materials and ceramics. Being produced in large amounts as aluminosilicate-rich secondary products, such as slags, they can be utilized for the formulation of AAMs. Slags are partially crystalline metallurgical residues produced during the high temperature separation of metallic and non-metallic materials in the steelmaking processes. In the present study, the electric arc furnace carbon or stainless steel slag (EAF) and secondary metallurgical slag such as ladle furnace basic slag (LS) were used as precursors in an alkali-activation process. EAF slag, with its amorphous fraction of about 56%, presented higher contents of soluble Si and Al species with respect to ladle slag R (35%). However, both are suitable to produce AAM. The leaching behavior shows that all the release values are below the regulation limit. All the bivalent ions (Ba, Cd, Cu, Ni, Pb, and Zn) are well immobilized in a geopolymeric matrix, while amphoteric elements, such as As and Cr, show a slight increase of release with respect to the corresponding slag in alkaline and aqueous environments. In particular, for Sb and As of AAM, release still remains below the regulation limits, while Mo presents an increase of leaching values that slightly exceeds the limit for landfill non-dangerous waste.

Four ruthenium complexes of clinically used zinc ionophore pyrithione and its oxygen analog 2-hydroxypyridine N-oxide were prepared and evaluated as inhibitors of enzymes of the aldo–keto reductase subfamily 1C (AKR1C). A kinetic study assisted with docking simulations showed a mixed type of inhibition consisting of a fast reversible and a slow irreversible step in the case of both organometallic compounds 1A and 1B. Both compounds also showed a remarkable selectivity towards AKR1C1 and AKR1C3 which are targets for breast cancer drug design. The organoruthenium complex of ligand pyrithione as well as pyrithione itself also displayed toxicity on the hormone-dependent MCF-7 breast cancer cell line with EC₅₀ values in the low micromolar range.

Two acetazolamide (AAZ) complexes with ruthenium(II) η⁶-p-cymene chloride were synthesised, characterised and tested for their inhibitory effects on several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with pharmacological applications. Against human (h) isoform hCA I, the two complexes showed inhibition constants in the range of 8.5–23.4 nM (AAZ has a K_I of 250 nM), against hCA II of 0.48–4.2 nM, whereas against hCA IX of 0.63–3.8 nM and against hCA XII of 0.04–0.52 nM, respectively. These highly effective ruthenium acetazolamide derivatives against the tumour-associated CA isoforms IX and XII warrant further in vivo studies, in hypoxic tumours overexpressing these enzymes.